When working with kinases, there are subtle but critical details that can make or break your research program. After supporting thousands of projects over 20+ years, here are three pitfalls we at SignalChem Biotech see time and time again.
1. Purity ≠ Activity
Just because a kinase looks pure on SDS-PAGE, HPLC, or Mass Spec doesn’t mean it’s functional.
Kinases require the right phosphorylation state, proper folding, cofactors, and minimal aggregation to actually work. Without those, you can end up with 98% purity and 0% activity.
Inactive kinases don’t just waste your time, they can generate misleading results. Binding assays may show false positives against dead protein, not true biological targets. At SCB, we prioritize active kinases so your assays reflect real biology.
2. Isoform Matters More Than You Think
Sometimes your kinase behaves oddly not because of the buffer, substrate, or inhibitor… but because you’re testing the wrong isoform.
Kinase genes often produce multiple isoforms through splicing. Each isoform can differ in activity, tissue expression, cofactor binding, and inhibitor sensitivity. Screening against a clean, pure, but biologically irrelevant isoform can derail months of work.
A quick sanity check:
- Is this isoform expressed in my system?
- Does it contain the domains needed for activity?
- Am I optimizing against the therapeutically relevant variant?
Switching to the right isoform can unlock insights instantly.
3. Panels Reveal What Single Screens Miss
Drug candidates rarely act on just one kinase. Off-target effects can drive safety concerns, or open doors to new indications.
That’s why kinase panels are powerful. Instead of testing one enzyme at a time, panels give you a strategic snapshot of how your compound behaves across receptor and non-receptor kinases.
Example: You design a JAK1 inhibitor that looks strong at nanomolar potency. Run it through a panel, and you discover moderate inhibition of ABL1 and TNK1. Suddenly, your risk assessment shifts—you can refine for selectivity or even explore dual-activity indications.
Our tyrosine kinase panel includes JAK1, ABL1, LCK, CSK, FLT1, DDR2, EPHA6, TNK1, and more—covering oncology, immunology, and angiogenesis targets. With 8 additional panels available, you can profile across the kinase landscape with confidence.
Takeaway
In drug discovery, the difference between success and failure often comes down to details: Is your kinase active? Is it the right isoform? Do you know what else your drug is hitting?
At SignalChem Biotech, we provide not just pure kinases, but active, biologically relevant isoforms, and comprehensive panels. Because better tools mean better decisions and fewer surprises in the clinic.
Explore our kinase catalog and panels: https://www.sinobiological.com/category/signaling/kinase-panels
